All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – Priothera Ltd. closed a €30 million (US$35.4 million) series A round to shepherd an oral sphingosine 1 phosphate (S1P) receptor agonist through clinical development in patients with acute myeloid leukemia (AML) who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT).